IMA203CD8

About Immatics Biotechnologies

Immatics Biotechnologies is a clinical-stage company dedicated to developing novel T cell receptor (TCR)-based immunotherapies for cancer. Founded in 2000, it has evolved from a platform-focused entity into a product-driven organization with a strategic focus on the PRAME antigen, expressed in over 50 cancer types. The company's integrated technology platforms enable the discovery of novel intracellular targets and the engineering of high-affinity TCRs against them, forming the basis for its pipeline of Adoptive Cell Therapies (ACT) and TCR Bispecifics. Its lead programs are advancing in clinical trials, positioning Immatics as a key player in the next generation of solid tumor oncology.

About Immatics

Immatics is a clinical-stage biotech company with a mission to develop novel, targeted immunotherapies for solid tumors. Its core achievement is building a dominant, multi-modality pipeline targeting PRAME, an antigen expressed in over 50 cancer types, using its proprietary XPRESIDENT® and XCEPTOR® discovery platforms. The company's strategy is to advance its lead TCR-T cell therapy (IMA203CD8) and bispecific TCR candidates through clinical development, leveraging its transatlantic operational footprint and strategic partnerships to bring precision oncology treatments to a broad patient population.

Therapeutic Areas

Other PRAME-positive solid tumors Drugs